Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Review of Graft-Versus-Host Disease
Description
Emily Baumer from the University of Pennsylvania delivered a comprehensive review of Graft-Versus-Host Disease (GVHD), discussing both acute and chronic forms of the condition. The presentation highlighted the importance of GVHD as a complication of allogeneic hematopoietic cell transplantation, affecting a significant number of recipients and leading to considerable morbidity and mortality. Baumer described the evolving classification system that enables distinction between acute and chronic GVHD based on clinical presentation rather than timing post-transplant. She explained the clinical features, diagnosis, and treatment strategies for both acute and chronic GVHD, emphasizing the new therapies available, including ruxolitinib for acute cases and other agents like ibrutinib and belumosidil for chronic cases. The presentation concluded with insights on the impact of chronic GVHD on patient prognosis, particularly through cutaneous manifestations, and the importance of effective management strategies to improve outcomes in this growing patient population.
View moreConclusions
- Graft-versus-host disease (GVHD) is a significant complication following allogeneic hematopoietic cell transplantation, affecting a large proportion of patients.
- The classification of acute and chronic GVHD helps guide treatment strategies, with differing pathophysiologies and management approaches for each.
- Acute GVHD primarily affects the skin, liver, and gastrointestinal tract, with specific clinical features that aid in diagnosis.
- New therapies such as ruxolitinib have shown promise for treating steroid-refractory acute GVHD, demonstrating improved patient outcomes compared to conventional therapies.
- Chronic GVHD has a higher burden of disease, with a median treatment duration of five years, and is linked to significant long-term morbidity and mortality.
- The severity of chronic skin GVHD can predict non-relapse mortality, highlighting the need for early recognition and management of skin manifestations.
- Advancements in GVHD therapy, including post-transplant cyclophosphamide and new FDA-approved agents, are contributing to better patient prognoses.
- Better understanding and categorization of GVHD assist clinicians in stratifying patient risk and deciding on more aggressive treatments for high-risk individuals.
- Majhail NS et al. BBMT 2013
- Malard, F et al. Nat Rev Dis Primers 9, 27 (2023)
- Baumrin E et al. J Am Acad Dermatol. 2024 Jan;90(1):1-16
- Byun et al. J Am Acad Dermatol (2011)
- Chanprapaph et al. Int J Dermatol (2021)
- Lee SJ et al. BBMT 2003
- Lee SJ et al. Hematology 2008
- Zeiser et al. N Engl J Med 2017
- Jagasia et al. Biol Blood Marrow Transplant 21 (2015) 389e401
- Miklos et al. Blood. 2017
- Buxbaum et al. Blood Advances. 2023